195 related articles for article (PubMed ID: 8600572)
21. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Fisher LM
Br J Cancer; 1993 Mar; 67(3):456-63. PubMed ID: 8382508
[TBL] [Abstract][Full Text] [Related]
22. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Lage H; Helmbach H; Dietel M; Schadendorf D
Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
24. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
25. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
Chen Z; Wang J; Zhang H; Liu D; Li Y; Xu Y; Tan D; Chen D; Zhao X; Wang G
Eur J Clin Invest; 2012 Mar; 42(3):310-20. PubMed ID: 21880040
[TBL] [Abstract][Full Text] [Related]
26. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2.
Matsumoto Y; Tamiya T; Nagao S
J Med Invest; 2005 Feb; 52(1-2):41-8. PubMed ID: 15751272
[TBL] [Abstract][Full Text] [Related]
27. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
28. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line.
Chan VT; Ng SW; Eder JP; Schnipper LE
J Biol Chem; 1993 Jan; 268(3):2160-5. PubMed ID: 8380592
[TBL] [Abstract][Full Text] [Related]
29. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
30. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
McPherson JP; Brown GA; Goldenberg GJ
Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
[TBL] [Abstract][Full Text] [Related]
32. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
33. Altered expression of DNA-topoisomerase IIalpha is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells.
Melixetian MB; Beryozkina EV; Pavlenko MA; Grinchuk TM
Leuk Res; 2000 Oct; 24(10):831-7. PubMed ID: 10996201
[TBL] [Abstract][Full Text] [Related]
34. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
35. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Oct; 92(10):1133-7. PubMed ID: 11676865
[TBL] [Abstract][Full Text] [Related]
36. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
37. A restriction fragment length polymorphism for human topoisomerase II: possible relationship to drug-resistance.
Zwelling LA; Mayes J; Deisseroth K; Hinds M; Grant G; Pathak S; Ledley FD; Vyas R; Hittelman W
Cancer Commun; 1990; 2(11):357-61. PubMed ID: 1978687
[TBL] [Abstract][Full Text] [Related]
38. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
40. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]